Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + thalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Daratumumab + thalidomide + dexamethasone is a combination regimen used primarily for the treatment of multiple myeloma, particularly in newly diagnosed patients eligible for autologous stem cell transplant. Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on myeloma cells, leading to their destruction through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. Thalidomide is an immunomodulatory agent that inhibits angiogenesis, modulates the immune system to enhance anti-myeloma activity, and directly suppresses tumor growth. Dexamethasone is a corticosteroid that induces apoptosis in myeloma cells and enhances the efficacy of other agents in the combination. This regimen has demonstrated significant efficacy in improving response rates and progression-free survival compared to regimens without daratumumab[1][3][4][5].
- Brand names
- DarzalexThalomidDecadron
- Other names
- D-Td (sometimes used in clinical trial shorthand)daratumumab + thalidomide + dexamethasone
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on daratumumab + thalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + thalidomide + dexamethasone.